Renaud Sabatier

Prognostic and predictive value of PDL1 expression in breast cancer

Renaud Sabatier, Pascal Finetti, Émilie Mamessier et al. · Oncotarget · 2014 · 496 citations · Full text

Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer

Ana Oaknin, Anna V. Tinker, Lucy Gilbert et al. · JAMA Oncology · 2020 · 346 citations · Full text

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

Kathleen N. Moore, Antoine Angelergues, Gottfried E. Konecny et al. · New England Journal of Medicine · 2023 · 316 citations · Full text

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study

Ana Oaknin, Lucy Gilbert, Anna V. Tinker et al. · Journal for ImmunoTherapy of Cancer · 2022 · 300 citations · Full text

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

François‐Clément Bidard, Anne‐Claire Hardy‐Bessard, Florence Dalenc et al. · The Lancet Oncology · 2022 · 285 citations

Breast Oncology, Esr1 Mutation, Endocrine-related Cancer +10